Abstract
Insulin resistance is a central pathophysiological axis of type 2 diabetes mellitus, obesity, metabolic syndrome, and several cardiometabolic conditions. With the advancement of precision endocrinology, this condition has increasingly been understood as a heterogeneous phenotype influenced by clinical, molecular, metabolomic, and therapeutic factors. This study aimed to systematically analyze advances in biomarkers and personalized therapies applied to insulin resistance, using a subgroup meta-analysis approach. A systematic literature review was conducted in recognized scientific databases, including studies on precision medicine, metabolic subclassification, classical biomarkers, metabolomic and molecular biomarkers, and personalized therapeutic interventions. Thirty-three studies were included and organized into four main domains: precision medicine and phenotypic subclassification; classical biomarkers, such as HOMA-IR, QUICKI, Matsuda index, and TyG index; emerging biomarkers, including branched-chain amino acids, α-hydroxybutyrate, metabolomic signatures, and microRNAs; and personalized therapies, such as intensive weight-loss interventions, metabolic surgery, GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists, and SGLT2 inhibitors. The findings showed that a subgroup-based approach is methodologically more appropriate given the heterogeneity of studies, populations, biomarkers, and interventions. Classical biomarkers remain useful for screening and initial stratification, whereas omics-based markers show potential for prognostic refinement and early identification of metabolic risk. Therapeutic interventions showed greater relevance when targeted to the patient’s clinical and metabolic profile. In conclusion, precision endocrinology applied to insulin resistance represents a promising frontier for early diagnosis, therapeutic personalization, prevention of type 2 diabetes, and reduction of cardiometabolic complications. Keywords: insulin resistance; precision endocrinology; biomarkers; personalized therapies.